Evaluation of late adverse events in long-term wilms' tumor survivors. 2010

Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
Department of Radiation Oncology, Academic Medical Center, Amsterdam, the Netherlands. i.w.vandijk@amc.uva.nl

OBJECTIVE To evaluate the prevalence and severity of adverse events (AEs) and treatment-related risk factors in long-term Wilms' tumor (WT) survivors, with special attention to radiotherapy. METHODS The single-center study cohort consisted of 185 WT survivors treated between 1966 and 1996, who survived at least 5 years after diagnosis. All survivors were invited to a late-effects clinic for medical assessment of AEs. AEs were graded for severity in a standardized manner. Detailed radiotherapy data enabled us to calculate the equivalent dose in 2 Gy fractions (EQD(2)) to compare radiation doses in a uniform way. Risk factors were evaluated with multivariate logistic regression analysis. RESULTS Medical follow-up was complete for 98% of survivors (median follow-up, 18.9 years; median attained age, 22.9 years); 123 survivors had 462 AEs, of which 392 had Grade 1 or 2 events. Radiotherapy to flank/abdomen increased the risk of any AE (OR, 1.08 Gy(-1) [CI, 1.04-1.13]). Furthermore, radiotherapy to flank/abdomen was associated with orthopedic events (OR, 1.09 Gy(-1) [CI, 1.05-1.13]) and second tumors (OR, 1.11 Gy(-1) [CI, 1.03-1.19]). Chest irradiation increased the risk of pulmonary events (OR, 1.14 Gy(-1) [CI, 1.06-1.21]). Both flank/abdominal and chest irradiation were associated with cardiovascular events (OR, 1.05 Gy(-1) [CI, 1.00-1.10], OR, 1.06 Gy(-1) [CI, 1.01-1.12]) and tissue hypoplasia (OR, 1.17 Gy(-1) [CI, 1.10-1.24], OR 1.10 Gy(-1) [CI, 1.03-1.18]). CONCLUSIONS The majority of AEs, overall as well as in irradiated survivors, were mild to moderate. Nevertheless, the large amount of AEs emphasizes the importance of follow-up programs for WT survivors.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D009381 Neoplasms, Radiation-Induced Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation. Radiation-Induced Cancer,Cancer, Radiation-Induced,Radiation-Induced Neoplasms,Cancer, Radiation Induced,Cancers, Radiation-Induced,Neoplasm, Radiation-Induced,Neoplasms, Radiation Induced,Radiation Induced Cancer,Radiation Induced Neoplasms,Radiation-Induced Cancers,Radiation-Induced Neoplasm
D009396 Wilms Tumor A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN. Bilateral Wilms Tumor,Nephroblastoma,Wilms Tumor 1,Wilms' Tumor,Nephroblastomas,Tumor, Bilateral Wilms,Tumor, Wilms,Tumor, Wilms',Wilm Tumor,Wilm's Tumor,Wilms Tumor, Bilateral
D011832 Radiation Injuries Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES. Radiation Sickness,Radiation Syndrome,Injuries, Radiation,Injury, Radiation,Radiation Injury,Radiation Sicknesses,Radiation Syndromes,Sickness, Radiation,Sicknesses, Radiation,Syndrome, Radiation,Syndromes, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems

Related Publications

Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
April 2019, Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
May 1991, The Journal of pediatrics,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
February 2024, Translational pediatrics,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
November 2023, Translational pediatrics,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
November 2013, Gan to kagaku ryoho. Cancer & chemotherapy,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
October 2017, Pediatric nephrology (Berlin, Germany),
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
November 2022, Pediatrics,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
January 1996, Oncology,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
October 2023, Translational pediatrics,
Irma W E M van Dijk, and Foppe Oldenburger, and Mathilde C Cardous-Ubbink, and Maud M Geenen, and Richard C Heinen, and Jan de Kraker, and Flora E van Leeuwen, and Helena J H van der Pal, and Huib N Caron, and Caro C E Koning, and Leontien C M Kremer
January 1982, Oncology,
Copied contents to your clipboard!